Trial Profile
A Randomised, Open-label Three-way Crossover Study to Evaluate the Pharmacokinetics of Salmeterol After Inhalation of a 25 μg and 50 μg Single Dose (Inhalation Powder, Hard PE Capsule for HandiHaler®2) and a 50 μg Single Dose (Serevent® Diskus®) in Healthy Male Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Oct 2014
Price :
$35
*
At a glance
- Drugs Salmeterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 09 Oct 2014 New trial record